niacinamide has been researched along with Hypertrophy, Right Ventricular in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hypertrophy, Right Ventricular: Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this paper was to examine the effects of nicotinamide (ND) and L-arginine (L-ARG) on pulmonary vascular and heart changes induced by pulmonary hypertension in rats in a gender-dependent way." | 7.96 | Protective effect of nicotinamide and L-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence. ( Jankowski, Z; Kocić, I; Sztormowska-Achranowicz, K, 2020) |
| "Sorafenib treatment (daily gavage, 2." | 5.35 | Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. ( Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA, 2008) |
| "The purpose of this paper was to examine the effects of nicotinamide (ND) and L-arginine (L-ARG) on pulmonary vascular and heart changes induced by pulmonary hypertension in rats in a gender-dependent way." | 3.96 | Protective effect of nicotinamide and L-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence. ( Jankowski, Z; Kocić, I; Sztormowska-Achranowicz, K, 2020) |
| "Progression of pulmonary hypertension is associated with the activation of the NNMT-MNA pathway in rats and humans." | 1.43 | Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension. ( Chlopicki, S; Fedorowicz, A; Jakubowski, A; Kopec, G; Kutryb-Zając, B; Mateuszuk, Ł; Skórka, T; Słomińska, E; Walczak, M; Zakrzewska, A; Łomnicka, M, 2016) |
| "Sorafenib treatment (daily gavage, 2." | 1.35 | Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. ( Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sztormowska-Achranowicz, K | 1 |
| Jankowski, Z | 1 |
| Kocić, I | 1 |
| Leong, ZP | 1 |
| Hikasa, Y | 1 |
| Fedorowicz, A | 1 |
| Mateuszuk, Ł | 1 |
| Kopec, G | 1 |
| Skórka, T | 1 |
| Kutryb-Zając, B | 1 |
| Zakrzewska, A | 1 |
| Walczak, M | 1 |
| Jakubowski, A | 1 |
| Łomnicka, M | 1 |
| Słomińska, E | 1 |
| Chlopicki, S | 1 |
| Moreno-Vinasco, L | 1 |
| Gomberg-Maitland, M | 1 |
| Maitland, ML | 1 |
| Desai, AA | 1 |
| Singleton, PA | 1 |
| Sammani, S | 1 |
| Sam, L | 1 |
| Liu, Y | 1 |
| Husain, AN | 1 |
| Lang, RM | 1 |
| Ratain, MJ | 1 |
| Lussier, YA | 1 |
| Garcia, JG | 1 |
4 other studies available for niacinamide and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Protective effect of nicotinamide and L-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence.
Topics: Animals; Arginine; Female; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular | 2020 |
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Respons | 2018 |
Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Animals; Case-Control Studies; Disease Models, Animal; Disease | 2016 |
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Complement C1q; Diseas | 2008 |